©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Identification of Residues 99, 220, and 221 of Human Cytochrome P450 2C19 as Key Determinants of Omeprazole Hydroxylase Activity (*)

(Received for publication, January 4, 1996; and in revised form, February 19, 1996)

Gordon C. Ibeanu Burhan I. Ghanayem Patricia Linko Leiping Li Lee G. Pedersen Joyce A. Goldstein (§)

From the NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Human P450 2C19 is selective for 4`-hydroxylation of S-mephenytoin and 5-hydroxylation of omeprazole, while the structurally homologous P450 2C9 has low activity toward these substrates. To identify the critical amino acids that determine the specificity of human P450 2C19, we constructed chimeras of P450 2C9 replacing various proposed substrate binding sites (SRS) with those of P450 2C19 and then replaced individual residues of P450 2C9 by site-directed mutagenesis. The 339 NH(2)-terminal amino acid residues (SRS-1-SRS-4) and amino acids 160-383 (SRS-2-SRS-5) of P450 2C19 conferred omeprazole 5-hydroxylase activity to P450 2C9. In contrast, the COOH terminus of P450 2C19 (residues 340-490 including SRS-5 and SRS-6), residues 228-339 (SRS-3 and SRS-4) and residues 292-383 (part of SRS-4 and SRS-5) conferred only modest increases in activity. A single mutation Ile His increased omeprazole 5-hydroxylase to 51% of that of P450 2C19. A chimera spanning residues 160-227 of P450 2C19 also exhibited omeprazole 5-hydroxylase activity which was dramatically enhanced by the mutation Ile His. A combination of two mutations, Ile His and Ser Pro, converted P450 2C9 to an enzyme with a turnover number for omeprazole 5-hydroxylation, which resembled that of P450 2C19. Mutation of Pro Thr enhanced this activity. Residue 99 is within SRS-1, but amino acids 220 and 221 are in the F-G loop and outside any known SRS. Mutation of these three amino acids did not confer significant S-mephenytoin 4`-hydroxylase activity to P450 2C9, although chimeras containing SRS-1-SRS-4 and SRS-2-SRS-5 of P450 2C19 exhibited activity toward this substrate. Our results thus indicate that amino acids 99, 220, and 221 are key residues that determine the specificity of P450 2C19 for omeprazole.


INTRODUCTION

The P450 (^1)cytochromes represent a ubiquitous superfamily of monooxygenases, which metabolize a vast array of endogenous and exogenous substrates(1, 2, 3) . Multiple P450 enzymes appear to have arisen from a single ancestral gene by duplication and diverged by mutation and gene conversion to produce families of structurally related enzymes with overlapping but often distinct substrate specificities. The regio- and stereoselectivity of specific enzymes for particular substrates appears to be encoded in certain defined regions of the primary sequence. Considerable progress has been made in recent years in elucidating the structural determinants of substrate specificity(4) . In some cases, substrate specificity between highly related members of the same subfamily has been shown to be defined by a few critical residues or even a single amino acid(5) .

P450 2C19 is a member of the human CYP2C subfamily, which includes four structurally related enzymes(6) . P450 2C9 and 2C19 are the most highly conserved of these forms, showing 91% structural identity, but have very distinctive substrate specificities. For example P450 2C19, which is polymorphic in man, is the principal enzyme responsible for the stereoselective 4`-hydroxylation of S-mephenytoin (7) and is highly selective for the 5-hydroxylation of the popular anti-ulcer drug omeprazole(46) . The structurally related P450 2C9 exhibits little activity toward either of these substrates, but exhibits a high turnover number for hydroxylation of tolbutamide and phenytoin and specifically 7-hydroxylates S-warfarin(6) . The present studies were designed to elucidate the key amino acids that determine the marked specificity of P450 2C19 for omeprazole and S-mephenytoin.

Since none of the mammalian P450 enzymes have been crystallized, the experimentally derived three-dimensional crystal structures of the bacterial enzymes, P450cam, P450BM-3, and P450terp, have served as models for predicting their structure and function. The current paradigm for such predictions has focused on alignment-based sequence similarities, alpha- and beta-secondary structure, hydropathy indices, computerized modeling based on the crystal structures of the bacterial P450 enzymes and protein engineering using chimeric constructs and site-directed mutagenesis(8, 9, 10, 11, 12) . Although the amino acid sequences of the soluble bacterial P450 differ considerably from those of the membrane-bound mammalian P450 enzymes, these methods have proven resourceful in identifying regions that determine the substrate specificities of the mammalian proteins.

Gotoh (13) predicted six potential substrate recognition sites (SRS) in the mammalian family 2 P450 enzymes based on an alignment with bacterial P450cam whose substrate-binding residues have been identified by x-ray crystallography and analysis of mutations that altered substrate specificity in experimental studies of the P450 2 subfamily. For example, site-directed mutagenesis studies have shown that the substrate and regiospecificity of the 2C subfamily of cytochrome P450 can be altered by substitution of critical amino acid residues at positions 112 to 115, 301, 359, 364(14, 15, 16, 17, 18, 19) . Replacement of residues 117, 209, 365, and 481 in the 2A subfamily (5, 20, 21, 22, 23) as well as residues 114, 206, 302, 363, 367, and 478 (24, 25, 26, 27, 28) in the 2B subfamily and residue 380 (29) in 2D1 have also been documented to alter substrate or regiospecificity.

To identify key amino acid residues responsible for the marked specificity of human P450 2C19 for two key substrates, omeprazole and S-mephenytoin, we constructed a total of 24 chimeras and mutant enzymes from the structurally related P450 2C9. Constructs were expressed in a yeast cDNA expression system. Initial chimeras replaced regions of P450 2C9 with similar segments of P450 2C19, using restriction enzymes sites located outside the six putative substrate binding domains proposed by Gotoh(13) . Subsequently, we used primary sequence alignment and comparative analysis of amino acid variations within the appropriate segments of the human P450 2C proteins to identify residues that might play a role in the substrate specificity of P450 2C19. Site-directed mutagenesis was then used to identify key residues responsible for the substrate specificity of P450 2C19.


EXPERIMENTAL PROCEDURES

Chemicals and Reagents

Restriction and modification enzymes were purchased from New England Biolabs and sequenase sequencing kits and deoxyadenosine 5`-[S]thiotriphosphate from Amersham Life Sciences. ^14C-Labeled omeprazole (53 mCi/mmol), a gift from Glaxo Research and Development (Hertfordshire, United Kingdom (UK)), was unstable and therefore periodically purified to 98% homogeneity by HPLC and stored at -70 °C under absolute ethanol. ^14C-Labeled S-mephenytoin (20.7 mCi/mmol) was prepared as described previously(7) . Purified P450 reductase was obtained from Human Biologics Inc., Phoenix, AZ.

Plasmids

The cloning of P450 2C9 and P450 2C19 into the yeast vector pAAH5 has been described previously(30) . To facilitate restriction enzyme manipulations, the modified cDNAs were recloned in both orientations in the HindIII site of pUC19. P450 2C9/2C19 hybrid clones were constructed by ligation of homologous fragments of the cDNA inserts. All plasmids were propagated in Escherichia coli DH5alpha (Life Technologies Inc.) and recombinant DNA identified by sequencing. The modified cDNAs were excised, inserted into pAAH5 vector, and recombinants in the correct orientation selected by restriction mapping and sequencing of the 5`-cloning junctions.

Site-directed Mutagenesis

Amino acid changes were introduced in P450 2C9 and the 2C9/2C19 hybrids using synthetic oligonucleotides (Table 1) containing the desired point mutations and a second primer, which abolished a unique restriction site in the pAAH5 plasmid. The procedure was essentially as described by Deng and Nickoloff (31) with minor modifications. The concentration of the plasmid selection oligonucleotide was reduced 5-fold in the annealing reaction. After extension with unmodified T7 DNA polymerase, the product was purified by Sephadex G50 spin column chromatography. BMH71-18, a mismatch repair-deficient bacteria strain, was transformed. Plasmid DNA isolated from the pooled colonies was digested to linearize non-mutated clones prior to retransformation in DH5alpha cells. Individual colonies were sequenced to confirm incorporation of the mutagenic primers.



Transformation of Yeast and Preparation of Recombinant Microsomes

The protease-deficient Saccharomyces cerevisiae strain 334 (MAT alpha pep4-3 prb1-1122 ura3-52 leu2-3 leu2-1222 reg1-501 gal11) was transformed with recombinant plasmids and Leu transformants selected as described previously(30, 32) . Microsomes were isolated from transformed yeast cells grown in synthetic broth, which did not contain leucine(32) , to mid-logarithmic growth phase essentially as described by Oeda et al.(33) with minor alterations(30) . Microsomal protein concentration (34) and P450 content (35) were determined as described previously.

Enzymatic Assays

S-Mephenytoin 4`-hydroxylation was assayed as described previously (7) except that cytochrome b(5) was not added to the reactions. To assay omeprazole 5-hydroxylase, recombinant yeast microsomes were preincubated at 37 °C for 5 min with purified P450 reductase (100 units/10 pmol of P450) and dilaurophosphatidylcholine (0.3 µg/pmol of P450) and then placed on ice. ^14C-Labeled omeprazole (400 µM, 22 mCi/mmol) was added to 50 mM HEPES buffer (pH 7.4) containing 0.1 mM EDTA and 1.5 mM MgCl(2). The reaction was preincubated at 37 °C with shaking for 5 min, initiated by addition of NADPH (2 mM), and terminated with equal volume of methanol after 15 min. After centrifugation, products were analyzed by reverse phase HPLC using an isocratic solvent phase consisting of 45 parts methanol and 55 parts water. Detection and quantitative analysis of radioactive peaks was accomplished through an on-line radiochemical detector.

Modeling and Structural Alignments

Omeprazole was docked into two structures using the molecular modeling package SYBYL at the Molecular Modeling Laboratory, University of North Carolina, Chapel Hill, NC. The first structure was a model for P450 2B1 described by Szklar et al.(19) , which is based on the x-ray structures of P450cam, P450terp, and P450BM-3. The second structure was that of P450cam. Omeprazole was docked into the binding pockets of both structures by requiring C19 of omeprazole to be 3-4 Å from the heme iron and rotating the substrate to minimize Van der Waals contacts with the protein. P450 2C9 and P450 2C19 were aligned with P450cam using GAP from the Wisconsin GCG package with standard defaults.


RESULTS AND DISCUSSION

Chimeras

Twenty-four chimeric 2C9/2C19 and mutant P450 2C9 proteins were analyzed for their ability to hydroxylate omeprazole and S-mephenytoin. The structures of the chimeras and their relationships to the SRS proposed by Gotoh (13) are shown in Fig. 1A. The 2C9/2C19 chimera exhibited only a slight increase in omeprazole 5`-hydroxylase activity over the wild-type P450 2C9, suggesting that the carboxyl terminus of P450 2C19 has relatively minor influence on its capacity to metabolize omeprazole (Fig. 2). Although this region encompasses SRS-5 and SRS-6, it contains some of the most highly conserved P450 domains including the heme-binding region. P450 cytochromes 2C9 and 2C19 differ by only 11 amino acids in this 152-residue domain, with a preponderance of conservative replacements. It is, therefore, not surprising that this region conferred only a small increase in omeprazole hydroxylase activity. In contrast, the chimeric 2C19/2C9 protein exhibited the largest (13-fold) increase in omeprazole 5-hydroxylase activity. The 2C19 segment of this chimera spanned the putative SRS-1-SRS-4 with 31 nonidentical residues, including 16 nonsynonymous changes. A nearly comparable increase was observed with the 2C9/2C19 chimera spanning SRS-2-SRS-5 of 2C19. The 2C19 region of these two chimeras overlap from residues 160-339, suggesting that this region may be requisite to substrate specificity. The 2C19/2C9 chimera contained 12 amino acid changes at the NH(2)-terminal end, which were not present in the 2C9/2C19 chimera, presumably accounting for the slightly higher activity of the former protein. Two other chimeric proteins containing only parts of the 160-383 fragment of 2C19, i.e. 2C9/2C19 (containing SRS-3 and SRS-4) and 2C9/2C19 (containing SRS-5 and part of SRS-4), exhibited a smaller increase (3-7-fold) in omeprazole hydroxylase activity than the 2C9/2C19 chimera, suggesting that the region spanning residues 160-227 of P450 2C19 could be involved in substrate specificity.


Figure 1: Schematic representation of the chimeric constructs (A) and site-directed mutants (B) of P450 2C9 and P450 2C19. A, the restriction enzyme sites utilized for chimeras and putative SRS (numbered 1-6) are indicated at the appropriate sites of P450 2C9 (top). Solid thin lines of the chimeras represent segments of P450 2C19, while bars represent the segments of P450 2C9. The site of an I99H mutation in a 2C9/2C19 chimera is indicated by a diamond. B, site-directed mutants of P450 2C9. The amino acids shown above the construct represent those of P450 2C9 which were mutated to the corresponding residues of P450 2C19 shown below the construct. The region 198-240 between SRS-2 and SRS-3 is expanded below. Residues that affected omeprazole hydroxylase activity are represented by diamonds.




Figure 2: Omeprazole 5-hydroxylase activity of chimeras of P450 2C9 and P450 2C19 expressed in yeast. Construction of chimeras is shown in Fig. 1. The omeprazole hydroxylase activity was measured as described under ``Experimental Procedures.''



Mutants

We initially generated five single amino acid mutants I99H (m1), Y243D (m3), M257I (m5), L362I (m4), and S451F (m2) and combinations of these mutations (m34, m45, m134, m145, m1245, and m1345) in P450 2C9 (Fig. 1B). Each amino acid was mutated to the corresponding amino acid in P450 2C19. The amino acids were chosen as residues that might be involved in substrate recognition based on alignment with P450cam and mouse 2A4/5 and selection of amino acids in P450 2C19 that were unique compared to other members of the P450 2C subfamily. Ile His was chosen because it is the only difference between P450 cytochromes 2C9 and 2C19 in SRS-1, and His is unique to P450 2C19. Ile is a unique amino acid in P450 2C19. Tyr Asp is a unique nonsynonymous amino acid change near SRS-3. Ile corresponds to contact residue Val in P450cam and is the only unique amino acid in SRS-5. Ser Phe is a unique nonsynonymous change located between SRS-5 and SRS-6. Of the single amino acid mutants, only I99H (Ile His) in SRS-1 increased omeprazole 5`-hydroxylase activity markedly (Fig. 3). The other mutations had essentially no effect. Multiple mutants containing the Ile His mutation had comparable activity to that of I99H. In contrast, multiple mutants m34 and m45, which did not contain the Ile His mutation, exhibited no increase in omeprazole hydroxylase activity (data not shown). Residue 99 maps to the interhelical region of B and B` helices, three residues from the NH(2) terminus of B`, which comprises part of the substrate-contact loop in the structure of P450cam (36, 37, 38) . Many mutations that alter the substrate specificity of members of the 2A, 2B, and 2C subfamilies of cytochrome P450 map to the B`-C interhelical region near the carboxyl terminus of SRS-1(5, 39, 40, 41, 42, 43) . Three-dimensional analysis of P450cam, P450terp, and P450BM-3 suggests that this substrate-contact loop, the largest in P450, extends from proximal end of the beta1-5 sheet through the distal end of the B`-C coil(8) . His of P450 2C19 corresponds to Pro of P450cam in the alignment of Gotoh(13) , which is one of three amino acids in SRS-1 that contact camphor. Moreover, it represents the only amino acid change between P450 2C9 and P450 2C19 in SRS-1 and is the only residue in SRS-1 that is unique to P450 2C19. This change involves the replacement of a nonpolar, hydrophobic isoleucine with a polar and possibly charged histidine residue. This polar histidine has the capacity for hydrogen bonding. It is possible that the residue is involved in substrate binding or alternatively changes the configuration of the active site. Comparison of P450 2C19 with a three-dimensional model of P450 2B1 (19) predicts that this amino acid would be approximately 15 Å from the center of the substrate binding pocket. Alternatively, when omeprazole is docked into binding pocket in the three-dimensional model of P450cam, we find that Pro (which aligns with His in 2C19) is near the docked substrate (approximately 6 Å) as shown in Fig. 4. Moreover, the adjacent Phe of P450cam is even closer to the substrate (2 Å). Thus, the effect of the Ile His mutation is consistent with this model.


Figure 3: Omeprazole 5-hydroxylase activities of site-directed mutants of P450 2C9. Omeprazole hydroxylase activity is given as the means ± S.E. The single mutations are numbered m1-m5, with amino acid substitutions indicated in parentheses, and m134, m145, m1345, and m1245 represent the corresponding multiple mutants. Three other mutant enzymes, m2 (S451F), m34, and m45 (not shown), did not affect omeprazole hydroxylase activity.




Figure 4: Model showing omeprazole docked in the substrate-binding pocket of P450cam. Thr is the highly conserved Thr in the I helix. The heme is shown in red, amino acid residues in blue, and substrate in black.



Analysis of Residues 160-227

Analysis of the chimeric data indicated that amino acids 160-227 may also play a crucial role in the specificity of P450 2C19 for omeprazole. We therefore constructed a 2C9/2C19 chimera and an identical construct containing an Ile His mutation. The 2C9/2C19 chimera exhibited a 7-fold increase in omeprazole 5-hydroxylase activity compared to P450 2C9 (Fig. 5). Moreover, when combined with the an Ile His mutation, this chimera exhibited a dramatic 38-fold increase in activity. The activity of this mutated chimera was even greater than that of native P450 2C19.


Figure 5: Analysis of the contribution of His and region 160-227 of 2C19 to omeprazole 5-hydroxylase activity using chimeras and site-directed mutants. The construction of the 2C9/2C19 chimera is shown in Fig. 1. A second 2C9/2C19 chimera contained the Ile His mutation. Individual amino acids in the 160-227 region were mutated in P450 2C9 in combination with the Ile His mutation as shown in Fig. 1B. Values represent means ± S.E.



We next sequentially modified amino acids in this region to those of the corresponding residues in P450 2C19 as shown in Fig. 1B. Six amino acids of P450 2C19 (three conservative and three nonconservative changes) differ from those of P450 2C9 between amino acids 160 and 227, with five of these mapping within 20 tandem amino acid residues of the carboxyl end of SRS-2. Mutations Lys Arg (K206R), Leu Val (L208V), Pro Thr (P221T), and Ser Thr in combination with Ile His did not increase omeprazole 5`-hydroxylase activity over that of I99H alone (Fig. 5), indicating that these residues are not the critical amino acids in this region. However, mutation of the polar serine at position 220 to a nonpolar hydrophobic proline residue (Ser Pro) increased activity to 90% of that of P450 2C19. When a second nonconservative mutation was made in the tandem residue at position 221 (P221T) in conjunction with S220P and I99H, the omeprazole hydroxylase activity of the triple mutant (I99H/S220P/P221T) was equivalent to that of P450 2C19. Sequence alignment indicates that residues 220 and 221 reside midway between the COOH-terminal end of the F-helix and the NH(2)-terminal end of G-helix in the interhelical loop, outside of any known substrate binding sites. This region corresponds to the F-G helical turn. This region is extremely variable in length in the P450 superfamily, and bacterial P450cam contains no amino acids corresponding to Pro or Thr of P450 2C19. The three-dimensional model of P450 2B1 would predict that these amino acids are far from the substrate-binding pocket; however, it has been suggested that this region may form a flexible lid over the substrate-binding pocket and thus form part of the substrate access channel(8, 11) . Proline residues give loops greater flexibility. Therefore, the introduction of Pro may refold the F-G loop and change accessibility to the active site or bring these residues closer to the substrate pocket. Interestingly, Uno and Imai (44) reported that residues 210-262, which contain part of the same domain, cooperate with amino acids 90-125 to confer substrate specificity to laurate (-1)-hydroxylase P450 2C2. Several other investigators have also identified important key residues in or near this domain, including residue 209 of mouse 2A5 as well as 206 and 209 of rat 2B1(5, 20, 22, 26, 45) . The present results clearly show that residues 220 and 221, which are in the F-G loop of human P450 2C19 and outside the SRS proposed by Gotoh(13) , are critical determinants of omeprazole hydroxylase activity.

S-Mephenytoin 4`-Hydroxylase Activity

Somewhat surprisingly, S-mephenytoin hydroxylase activity did not parallel omeprazole hydroxylase activity in the various chimeras and mutants. As shown in Fig. 6, only two chimeric proteins, 2C19/2C9 and 2C9/2C19, exhibited significant increases in S-mephenytoin hydroxylase activity over P450 2C9. Activities of these proteins were 30% of that of P450 2C19. Furthermore, S-mephenytoin hydroxylase activity was not detected in any of the mutant proteins (data not shown). The differences in activity of the His mutants toward S-mephenytoin and omeprazole could be due to the fact that although S-mephenytoin is a smaller molecule (16 heavy atoms) than omeprazole (24 heavy atoms), it is more branched. The side chain of histidine can potentially interact with both omeprazole and mephenytoin since it has the capacity for hydrogen bonding, whereas this cannot happen with isoleucine. When S-mephenytoin is docked with the 4-position of the phenyl ring replacing the 5-position of omeprazole (Fig. 4), the remaining rings of both molecules would be placed in an orientation that could allow strong hydrogen bonding with His. However, the branched structure of S-mephenytoin may require additional three-dimensional accommodation in the active site. These results suggest that specificity of P450 2C19 for S-mephenytoin may require a more complex enzyme configuration than that for omeprazole, possibly involving multiple substrate recognition domains acting in concert.


Figure 6: S-Mephenytoin 4`-hydroxylase activity of chimeric and mutant CYP2C9 proteins expressed in yeast. Chimeras and mutants are identical to those shown in Fig. 2and Fig. 5. None of the other mutants shown in Fig. 1B, Fig. 3, and Fig. 4increased mephenytoin hydroxylase activity (data not shown).



Conclusions

Chimeric proteins and amino acid mutations have been widely used to determine critical residues responsible for substrate specificity of closely related P450 proteins. We have utilized this approach to identify amino acids that are critical determinants of omeprazole 5-hydroxylase activity of human P450 2C19. We first identified regions important in substrate specificity by analyzing the catalytic activity of chimeras and then sequentially replaced individual residues in P450 2C9 by site-directed mutagenesis. We have identified three key amino acids at positions 99, 220, and 221, which are critical determinants of omeprazole 5-hydroxylase activity. These residues map to SRS-1 and the F-G loop.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: NIEHS, National Institutes of Health, P. O. Box 12233, Research Triangle Park, NC 27709. Tel.: 919-541-4495; Fax: 919-541-3647.

(^1)
The abbreviations used are: P450, cytochrome P450; SRS, substrate recognition site(s); HPLC, high pressure liquid chromatography.


ACKNOWLEDGEMENTS

We express our gratitude to Glaxo Research and Development (Hertfordshire, UK) for the generous gift of ^14C-labeled omeprazole. We also thank Dr. James R. Halpert, University of Arizona, Tucson, for generously providing the coordinates for a structural model of cytochrome P450 2B1 (19) and for a preprint of a manuscript in press(19) . We thank Tamara McIntyre, Heath LeFevers, and Angela Stanley for HPLC analysis of omeprazole metabolites.


REFERENCES

  1. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunzsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. (1993) DNA Cell Biol. 12, 1-51 [Medline] [Order article via Infotrieve]
  2. Porter, T. D., and Coon, M. J. (1991) J. Biol. Chem. 266, 13469-13472 [Free Full Text]
  3. Guengerich, F. P. (1991) J. Biol. Chem. 266, 10019-10022 [Free Full Text]
  4. Johnson, E. F. (1992) Trends Phamacol. Sci. 13, 122-126 [CrossRef][Medline] [Order article via Infotrieve]
  5. Lindberg, R., and Negishi, M. (1989) Nature 339, 632-634 [CrossRef][Medline] [Order article via Infotrieve]
  6. Goldstein, J. A., and de Morais, S. M. F. (1994) Pharmacogenetics 4, 285-299 [Medline] [Order article via Infotrieve]
  7. Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., and Ghanayem, B. I. (1994) Biochemistry 33, 1743-1752 [Medline] [Order article via Infotrieve]
  8. Hasemann, C. A., Kurumbali, R. G., Boddupalli, S. S., Peterson, J. A., and Diesenhofer, J. (1995) Structure (Lond.) 3, 41-62
  9. Laughton, C. A., Neidle, S., Zvelebil, M. J., and Sternberg, J. M. (1990) Biochem. Biophys. Res. Commun. 171, 1160-1167 [Medline] [Order article via Infotrieve]
  10. Laughton, C. A., Zvelebil, M. J., and Neidle, S. (1993) J. Steroid Biochem. Mol. Biol. 44, 399-407 [Medline] [Order article via Infotrieve]
  11. Lewis, D. F. V., and Moereels, H. (1992) J. Comput.-Aided. Mol. Design 6, 235-252
  12. Zvelebil, M. J., Wolf, J. M., and Sternberg, M. J. E. (1991) Protein Eng. 4, 271-282 [Abstract]
  13. Gotoh, O. (1992) J. Biol. Chem. 267, 83-90 [Abstract/Free Full Text]
  14. Straub, P., Lloyd, M., Johnson, E. F., and Kemper, B. (1993) J. Biol. Chem. 268, 21997-22003 [Abstract/Free Full Text]
  15. Straub, P., Johnson, E. F., and Kemper, B. (1993) Arch. Biochem. Biophys. 306, 521-527 [CrossRef][Medline] [Order article via Infotrieve]
  16. Imai, Y., and Nakamura, M. (1989) Biochem. Biophys. Res. Commun. 158, 717-722 [Medline] [Order article via Infotrieve]
  17. Sullivan, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J., and Goldstein, J. A. (1996) Pharmacogenetics , in press
  18. Richardson, T. H., and Johnson, E. F. (1994) J. Biol. Chem. 269, 23937-23943 [Abstract/Free Full Text]
  19. Szklar, G. D., He, Y.-a., and Halpert, J. R. (1995) Biochemistry, 34, 14312-14322
  20. Juvonen, R. O., Iwasaki, M., and Negishi, M. (1991) J. Biol. Chem. 266, 16431-16435 [Abstract/Free Full Text]
  21. Iwasaki, M., Lindberg, R. L. P., Juvonen, R. D., and Negishi, M. (1993) Biochem. J. 291, 569-573 [Medline] [Order article via Infotrieve]
  22. Iwasaki, M., Darden, T. A., Pedersen, L. G., Davis, D. G., Juvonen, R. O., Sueyoshi, T., and Negishi, M. (1993) J. Biol. Chem. 268, 759-762 [Abstract/Free Full Text]
  23. Iwasaki, M., Darden, T. A., Pedersen, L. G., and Negishi, M. (1995) Biochemistry 3, 5054-5059
  24. Aoyama, T., Korzekwa, K., Nagata, K., Adesnik, M., Reiss, A., Lapenson, D. P., Gillette, J., Gelboin, H. V., Waxman, D. J., and Gonzalez, F. J. (1989) J. Biol. Chem. 264, 21327-21333 [Abstract/Free Full Text]
  25. Kedzie, K. M., Balfour, C. A., Escobar, G. Y., Grimm, S. W., He, Y., Pepperil, D. J., Regan, J. W., Stevens, J. C., and Halpert, J. R. (1991) J. Biol. Chem. 266, 22515-22521 [Abstract/Free Full Text]
  26. He, Y-a., Luo, Z., Klekotka, P. A., Burnett, V. L., and Halpert, J. R. (1994) Biochemistry 33, 4419-4424 [Medline] [Order article via Infotrieve]
  27. Halpert, J. R., and He, Y. (1993) J. Biol. Chem. 268, 4453-4457 [Abstract/Free Full Text]
  28. Hasler, J. A., Harlow, G. R., Szklar, G. D., John, G. H., Kedzie, K. M., Burnett, V. L., Kaminsky, L. S., and Halpert, J. R. (1994) Mol. Pharmacol. 46, 338-345 [Abstract]
  29. Matsunaga, E., Zeugin, T., Zanger, U. M., Aoyama, T., Meyer, U. A., and Gonzalez, F. J. (1990) J. Biol. Chem. 265, 17197-17201 [Abstract/Free Full Text]
  30. Faletto, M. B., Linko, P., and Goldstein, J. A. (1992) J. Biol. Chem. 267, 2032-2037 [Abstract/Free Full Text]
  31. Deng, W. P., and Nickoloff, J. A. (1992) Anal. Biochem. 200, 81-88 [Medline] [Order article via Infotrieve]
  32. Rose, M. D., Winson, F., and Hieter, P. (1990) in Methods in Yeast Genetics (Rose, M. D., Winson, F., and Hieter, P., eds) pp. 180-187, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  33. Oeda, K., Sakaki, T., and Ohkawa, H. (1985) DNA (N. Y.) 4, 203-210 [Medline] [Order article via Infotrieve]
  34. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  35. Omura, T., and Sato, R. (1964) J. Biol. Chem. 239, 2370-2378 [Free Full Text]
  36. Poulos, T. L., Finzel, B. C., and Howard, A. J. (1987) J. Mol. Biol. 195, 687-700 [Medline] [Order article via Infotrieve]
  37. Atkins, W. M., and Sligar, S. G. (1988) J. Biol. Chem. 263, 18842-18849 [Abstract/Free Full Text]
  38. Nelson, D. R., and Strobel, H. W. (1989) Biochemistry 28, 656-660 [Medline] [Order article via Infotrieve]
  39. Lin, D., Black, S. M., Nagahama, Y., and Miller, W. M. (1993) Endocrinology 132, 2498-2506 [Abstract]
  40. Kronbach, T., Larabee, T. M., and Johnson, E. F. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8262-8265 [Abstract]
  41. Kronbach, T., Kemper, B., and Johnson, E. F. (1991) Biochemistry 30, 6097-6102 [Medline] [Order article via Infotrieve]
  42. Uno, T., and Imai, Y. (1992) J. Biochem. (Tokyo) 112, 155-162
  43. Johnson, E. F., Kronbach, T., and Hsu, M.-h. (1992) FASEB J. 6, 700-705 [Abstract/Free Full Text]
  44. Uno, T., and Imai, Y. (1989) J. Biochem. (Tokyo) 106, 569-574
  45. Luo, Z., He, Y.-a., and Halpert, J. R. (1994) Arch. Biochem. Biophys. 309, 52-57 [CrossRef][Medline] [Order article via Infotrieve]
  46. Ghanayem, B. I., Karam, W. G., and Goldstein, J. A. (1994) Sixth North American International Society for the Study of Xenobiotics Meeting, October 23-27, 1994, Raleigh, NC , (abstr.), p. 50

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.